Targeted Oncology reviews trending news online for the week of June 5, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.
In oncology news, the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program took place on May 29-31, 2020, with the publication of thousands of abstracts and new data. Targeted Oncology covered many of these presentations throughout the week across various cancer types. ASCO utilized a virtual platform this year due to the coronavirus disease 2019 (COVID-19) pandemic and subsequent travel and social distancing restictions.
Following this year’s meeting, several oncology experts spoke with Targeted Oncology on some of the most impactful data they saw during the meeting. These include updates in genitourinary, gastrointestinal, lung, gynecologic, and breast cancers, as well as in hematologic malignancies.
Pralsetinib (BLU-667) demonstrated significant efficacy across various advanced solid tumor types harboring RET alterations, including in patients with difficult-to-treat cancers, according to findings from a subgroup of the ongoing phase 1/2 ARROW trial.
Early signals of anti-tumor activity and safety were demonstrated with AMG 510 in patients with multiple advanced solid tumors harboring KRAS G12C mutations.
Because of the strain on the health care system brought on by the COVID-19 pandemic, the ASCO and the National Comprehensive Cancer Network (NCCN) have laid out guidelines to help practicing oncologists delineate the best ways to allocate limited resources.
A daily 160 mg dose of osimertinib (Tagrisso) was well-tolerated and demonstrated clinical activity in patients with EGFR exon 20-mutant non–small cell lung cancer in the phase 2 ECOG-ACRIN 5162 trial.
Targeted Oncology pulled together all the FDA news from May 2020, which appeared to be an exciting month for oncology with many updates from the FDA. In particular, the FDA granted 4 approvals on Friday, May 15, 2020, alone.
Mansoor Raza Mirza, MD, of the Rigshospitalet–Copenhagen University Hospital in Denmark, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Ramez Eskander, MD, of Moores Cancer Center, presented the case of a 68-year-old woman with stage IV ovarian cancer and discussed the management approach for this patient and similar cases.
The risk for death from COVID-19 was greater for patients with stable cancer compared with patients who had no evidence of disease.
The risk of death in patients with thoracic cancer was inflated with the administration of chemotherapy within 3 months of a COVID-19 diagnosis, findings from the global TERAVOLT Consortium registry show.
A group of physicians in gynecologic oncology spoke to the challenges they have seen in their clinics in the face of the COVID-19 pandemic.